Arranon Phase II Data Appear Adequate For Accelerated Approval, FDA Indicates
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Oncologic Drugs Advisory Committee will consider accelerated approval of GSK's antineoplastic agent nelarabine for T-Cell leukemia and lymphoma on Sept. 14.
You may also be interested in...
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
AstraZeneca Continues Pipeline Expansion Via Two Licensing Deals Totaling $800 Million
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.
Pharmion’s Vidaza Approved For IV Administration
Supplemental approval for the new route of administration will offer physicians less reimbursement risk, firm tells “The Pink Sheet” DAILY.